Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: Importance of peroxisome proliferator-activated receptor γ expression

Journal of Nutritional Biochemistry

Volumn 22, Issue 12, 2011, Pages 1160-1171

  Mazzei, Joseph C ^a   Zhou, Hui ^a   Brayfield, Bradley P ^a   Hontecillas, Raquel ^a   Bassaganya Riera, Josep ^a   Schmelz, Eva M ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

CD4+ T cells; Colon cancer; Inflammation; Macrophages; Sphingomyelin

Indexed keywords

AZOXYMETHANE; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SPHINGOMYELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DISEASE ACTIVITY; ENTERITIS; GENOTYPE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; MACROPHAGE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TH1 CELL; TH17 CELL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTICARCINOGENIC AGENTS; COLONIC NEOPLASMS; DEXTRAN SULFATE; EPITHELIAL CELLS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; MACROPHAGES; MICE; PPAR GAMMA; SPHINGOMYELINS; UP-REGULATION;

MUS;

EID: 81255142144     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2010.09.017     Document Type: Article

References (64)

1. SEER cancer statistics review, 1975-2006 2009, National Cancer Institute, Bethesda (MD), based on November 2008 SEER data submission, posted to the SEER web site. http://seer.Cancer.Gov/csr/1975_2006/, M.J.R.L. Horner, M. Krapcho, N. Neyman, R. Aminou, N. Howlader, S.F. Altekruse, E.J. Feuer, L. Huang, A. Mariotto, B.A. Miller, D.R. Lewis, M.P. Eisner, D.G. Stinchcomb, B.K. Edwards (Eds.).
2. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000 2006, 123-134. National Cancer Institute, Bethesda (Md), [NIH Pub. 06-5767]. A.O.L.M. Bleyer, R. Barr, L.A.G. Ries (Eds.).
3. Lakatos P.L., Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008, 14:3937-3947.
4. WCRF/AICR Nutrition, physical activity and the prevention of cancer: a global perspective 2007, AICR, Washington (DC).
5. Schmelz E.M., Bushnev A.S., Dillehay D.L., Liotta D.C., Merrill A.H. Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Nutr Cancer 1997, 28:81-85.
6. Schmelz E.M., Bushnev A.S., Dillehay D.L., Sullards M.C., Liotta D.C., Merrill A.H. Ceramide-beta-d-glucuronide: synthesis, digestion, and suppression of early markers of colon carcinogenesis. Cancer Res 1999, 59:5768-5772.
7. Schmelz E.M., Sullards M.C., Dillehay D.L., Merrill A.H. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated cf1 mice. J Nutr 2000, 130:522-527.
8. Lemonnier L.A., Dillehay D.L., Vespremi M.J., Abrams J., Brody E., Schmelz E.M. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch Biochem Biophys 2003, 419:129-138.
9. Symolon H., Schmelz E.M., Dillehay D.L., Merrill A.H. Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated cf1 mice and apcmin/+ mice. J Nutr 2004, 134:1157-1161.
10. Schmelz E.M., Roberts P.C., Kustin E.M., et al. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 2001, 61:6723-6729.
11. Nilsson A. Metabolism of sphingomyelin in the intestinal tract of the rat. Biochim Biophys Acta 1968, 164:575-584.
12. Nilsson A. The presence of spingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. Biochim Biophys Acta 1969, 176:339-347.
13. Ohlsson L., Hertervig E., Jonsson B.A., et al. Sphingolipids in human ileostomy content after meals containing milk sphingomyelin. Am J Clin Nutr 2010.
14. Schmelz E.M., Crall K.J., Larocque R., Dillehay D.L., Merrill A.H. Uptake and metabolism of sphingolipids in isolated intestinal loops of mice. J Nutr 1994, 124:702-712.
15. Bartke N., Hannun Y.A. Bioactive sphingolipids: metabolism and function. J Lipid Res 2009, 50(Suppl):S91-S96.
16. Duan R.D., Nilsson A. Metabolism of sphingolipids in the gut and its relation to inflammation and cancer development. Prog Lipid Res 2009, 48:62-72.
17. Lin C.I., Chen C.N., Lin P.W., Lee H. Sphingosine 1-phosphate regulates inflammation-related genes in human endothelial cells through s1p1 and s1p3. Biochem Biophys Res Commun 2007, 355:895-901.
18. Wu D., Ren Z., Pae M., et al. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue. J Immunol 2007, 179:4829-4839.
19. Teichgraber V., Ulrich M., Endlich N., et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008, 14:382-391.
20. Claycombe K.J., Wu D., Nikolova-Karakashian M., et al. Ceramide mediates age-associated increase in macrophage cyclooxygenase-2 expression. J Biol Chem 2002, 277:30784-30791.
21. Bauer J., Liebisch G., Hofmann C., et al. Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression. PLoS One 2009, e7197:4.
22. Exon J.H., South E.H. Effects of sphingomyelin on aberrant colonic crypt foci development, colon crypt cell proliferation and immune function in an aging rat tumor model. Food Chem Toxicol 2003, 41:471-476.
23. Furuya H., Ohkawara S., Nagashima K., Asanuma N., Hino T. Dietary sphingomyelin alleviates experimental inflammatory bowel disease in mice. Int J Vitam Nutr Res 2008, 78:41-49.
24. Desreumaux P., Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 2006, 24(Suppl 1):2-9.
25. Mangelsdorf D.J., Thummel C., Beato M., et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
26. Bassaganya-Riera J., Guri A., King J., Hontecillas R. Peroxisome proliferator-activated receptors: the nutritionally controlled molecular networks that integrate inflammation, immunity and metabolism. Curr Nutr Food Sci 2005, 1:179-187.
27. Guri A.J., Hontecillas R., Bassaganya-Riera J. Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition. Clin Nutr 2006, 25:871-885.
28. Hontecillas R., Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007, 178:2940-2949.
29. Evans N.P., Misyak S.A., Schmelz E.M., Guri A.J., Hontecillas R., Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr 2010, 140:515-521.
30. Guri A.J., Evans N.P., Hontecillas R., Bassaganya-Riera J. T cell PPAR gamma is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem 2010, [ePub ahead of press]. 10.1016/j.jnutbio.2010.06.011.
31. Barak Y., Nelson M.C., Ong E.S., et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4:585-595.
32. Akiyama T.E., Sakai S., Lambert G., et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and ApoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002, 22:2607-2619.
33. Cui Y., Miyoshi K., Claudio E., et al. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002, 277:17830-17835.
34. Bassaganya-Riera J., Reynolds K., Martino-Catt S., et al. Activation of ppar gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 2004, 127:777-791.
35. Guri A.J., Hontecillas R., Ferrer G., et al. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J Nutr Biochem 2008, 19:216-228.
36. Nutrition AIo Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1977, 107:1340-1348.
37. Schmelz E.M., Dillehay D.L., Webb S.K., Reiter A., Adams J., Merrill A.H. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 1996, 56:4936-4941.
38. Kobayashi T., Shimizugawa T., Osakabe T., Watanabe S., Okuyama H. A long-term feeding of sphingolipids affected the levels of plasma cholesterol and hepatic triacylglycerol but not tissue phospholpids and sphingolipids. Nutr Res 1997, 17..
39. Simon K.W., Tait L., Miller F., et al. Suppression of breast xenograft growth and progression in nude mice: implications for the use of orally administered sphingolipids as chemopreventive agents against breast cancer. Food & Function 2010, 1:90-98.
40. Vetuschi A., Latella G., Sferra R., Caprilli R., Gaudio E. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 2002, 47:1447-1457.
41. Zhong J., Eckhardt E.R., Oz H.S., Bruemmer D., de Villiers W.J. Osteopontin deficiency protects mice from dextran sodium sulfate-induced colitis. Inflamm Bowel Dis 2006, 12:790-796.
42. Costantino E., Maddalena F., Calise S., et al. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett 2009, 279:39-46.
43. Pettersson A., Nylund G., Khorram-Manesh A., Nordgren S., Delbro D.S. Nicotine induced modulation of SLURP-1 expression in human colon cancer cells. Auton Neurosci 2009, 148:97-100.
44. Jeong C.H., Bode A.M., Pugliese A., et al. [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res 2009, 69:5584-5591.
45. Ihara A., Wada K., Yoneda M., Fujisawa N., Takahashi H., Nakajima A. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007, 103:24-32.
46. Joshi N., Johnson L.L., Wei W.Q., et al. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res 2006, 66:6851-6860.
47. Kloth J.N., Gorter A., Fleuren G.J., et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol 2008, 215:222-230.
48. Niedzielska I., Niedzielski Z., Tkacz M., et al. Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J Physiol Pharmacol 2009, 60((Suppl 1)):65-71.
49. Ohlsson L., Burling H., Nilsson A. Long term effects on human plasma lipoproteins of a formulation enriched in butter milk polar lipid. Lipids Health Dis 2009, 8:44.
50. Dillehay D.L., Webb S.K., Schmelz E.M., Merrill A.H. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 1994, 124:615-620.
51. Meydani S.N., Wu D. Nutrition and age-associated inflammation: implications for disease prevention. JPEN J Parenter Enteral Nutr 2008, 32:626-629.
52. Prasad V.V., Nithipatikom K., Harder D.R. Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes. Neurochem Int 2008, 53:220-229.
53. Mizushima T., Ito T., Kishi D., et al. Therapeutic effects of a new lymphocyte homing reagent fty720 in interleukin-10 gene-deficient mice with colitis. Inflamm Bowel Dis 2004, 10:182-192.
54. Deguchi Y., Andoh A., Yagi Y., et al. The s1p receptor modulator fty720 prevents the development of experimental colitis in mice. Oncol Rep 2006, 16:699-703.
55. Wei G., Wei L., Zhu J., et al. Global mapping of h3k4me3 and h3k27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009, 30:155-167.
56. Sarra M., Pallone F., Macdonald T.T., Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 2010, 16:1808-1813.
57. Reynolds J.M., Pappu B.P., Peng J., et al. Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease. Immunity 2010, 32:692-702.
58. Hontecillas R., Bassaganya-Riera J., Wilson J., Hutto D.L., Wannemuehler M.J. CD4+ T-cell responses and distribution at the colonic mucosa during brachyspira hyodysenteriae-induced colitis in pigs. Immunology 2005, 115:127-135.
59. Wendelsdorf K, Bassaganya-Riera J, Hontecillas R, Eubank S. Model Of Colonic Inflammation: Immune Modulatory Mechanisms In Inflammatory Bowel Disease. J Theor Biol 264:1225-39.
60. Odegaard J.I., Ricardo-Gonzalez R.R., Goforth M.H., et al. Macrophage-specific ppargamma controls alternative activation and improves insulin resistance. Nature 2007, 447:1116-1120.
61. Odegaard J.I., Ricardo-Gonzalez R.R., Red Eagle A., et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 2008, 7:496-507.
62. Kang K., Reilly S.M., Karabacak V., et al. Adipocyte-derived Th2 cytokines and myeloid ppardelta regulate macrophage polarization and insulin sensitivity. Cell Metab 2008, 7:485-495.
63. Bassaganya-Riera J., Misyak S., Guri A.J., Hontecillas R. PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. Cell Immunol 2009, 258:138-146.
64. Hanavadi S., Martin T.A., Watkins G., Mansel R.E., Jiang W.G. The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast cancer. Ann Surg Oncol 2007, 14:2159-2166.